1.. Resource table {#S1}
==================

  Name of stem cell construct                                         I2--12F
  ------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  Institution                                                         Edith Nourse Rogers Memorial Veterans Hospital
  Person who created resource                                         Han-Kyu Lee, Weiming Xia
  Contact person and email                                            Weiming Xia, <Weiming.Xia@va.gov>
  Date archived/stock date                                            May 14, 2015
  Origin                                                              Human peripheral blood mononuclear cells (PBMCs)
  Type of resource                                                    Induced pluripotent stem cell (iPS); derived from human peripheral blood mononuclear cells (PBMCs)
  Sub-type                                                            Induced pluripotent stem cell (iPS)
  Key transcription factors                                           Oct4, Sox2, cMyc, Klf4
  Authentication                                                      Identity and purity of cell line confirmed ([Fig. 2](#F2){ref-type="fig"})
  Link to related literature (direct URL links and full references)   Not available
  Information in public databases                                     Not available

2.. Resource details {#S2}
====================

The blood sample was donated by the patient who was hospitalized at the Bedford VA Hospital Special Dementia Care Unit, which is a hospice unit staffed and managed by the Bedford Geriatric Research, Education and Clinical Center (GRECC).

The patient exhibited memory deficit at age 59 that prevented him from performing job-related function. Subsequent neurological tests and positron emission tomography (PET) scan presented clinical diagnosis consistent with Alzheimer\'s disease. The patient also suffered two witnessed seizures which were controlled by anti-epileptic drug levetiracetam. The study was approved by the Bedford Veterans Affairs Hospital Institutional Review Board under the project title, "iPSC for Neurodegenerative diseases".

Peripheral blood mononuclear cells (PBMC) were separated from whole blood and transduced by reprogramming vectors carrying four Yamanaka factors, Oct4, Sox2, Klf4, and c-Myc included in the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Invitrogen). The four Yamanaka factors have been well documented for efficient reprogramming of skin fibroblasts and blood cells ([@R15]; [@R9]; [@R14]).

We confirmed development of human iPSC by karyotyping ([Fig. 1](#F1){ref-type="fig"}), which is a standard procedure to authenticate normal karyotypes of cells ([@R8]). To validate bona fide iPSCs in our culture that is distinguishable from only partially transduced cells, we examined the expression of cell surface proteins, such as sialylated keratan sulfate antigens Tra-1-81 and Tra-1-60, which defines a human embryonic stem cell ([@R1]; [@R10]; [@R13]). Immunocytochemical staining using antibody against stem cell marker TRA-1-81 ([Fig. 2A](#F2){ref-type="fig"}) and Tra-1-60 (not shown) was performed to confirm the purity and pluripotency of our iPSC.

Many approaches have been developed to produce footprint-free iPSC ([@R11]), and we applied the CytoTune-iPS 2.0 Reprogramming System for our studies ([@R12]). This system uses vectors that remain in the cytoplasm ([@R7]) and do not integrate into host genome ([@R4]). Therefore, the host cell can be cleared of the vectors and reprogramming factor genes ([@R7]). We searched for any remaining SeV protein by immunocytochemical staining using Anti-SeV antibody (MBL international) and confirmed that there is no trace of viral protein ([Fig. 2B](#F2){ref-type="fig"}).

To demonstrate capacity of iPSC for three germ layer differentiation, we tested formation of embryoid body (EB) ([@R5]). We performed immunostaining using three different antibodies corresponding to three germ layers, i.e., ectoderm: βIII tubulin antibody, mesoderm: smooth muscle actin (SMA) antibody, endoderm: α-fetoprotein (AFP) antibody. Our results demonstrated differentiation capacity of newly converted iPSC ([Fig. 3](#F3){ref-type="fig"}).

3.. Materials and methods {#S3}
=========================

3.1.. Human blood sample {#S4}
------------------------

Blood was collected in Vacutainer cell preparation tube (CPT) (Becton, Dickinson and Company, Franklin Lakes, NJ). PBMCs were prepared within 1 h of blood collection. Blood samples were centrifuged at 1500 rcf for 20 min at room temperature, and the PBMC were collected and transferred to a fresh tube, washed with PBS, and centrifuged at 300 rcf for 10 min at room temperature. Cell pellets were re-suspended in PBMC medium (Invitrogen) containing growth factors for transduction.

3.2.. iPSC generation and expansion {#S5}
-----------------------------------

Induced PSCs were generated from freshly collected, peripheral blood-derived PBMCs ([@R3]). Cells were transduced with Sendai virus particles containing four Yamanaka factors using the integration-free CytoTune-iPS Sendai Reprogramming Kit ([@R9]; [@R14]). Transduced cells were plated with mouse embryonic fibroblast (MEF) feeder cells. Cells were fed with iPSC medium containing bFGF (Invitrogen) until small colonies were formed in 2 weeks. Growth of small colonies was maintained for another two weeks before each colony was picked for expansion into individual iPSC lines. After successful formation of iPSC colonies, iPSCs were transferred to plates coated with Geltrex (Invitrogen) and expanded in E8 medium (Invitrogen).

3.3.. Live staining of iPSC {#S6}
---------------------------

Purity and pluripotency of iPSCs grown on both MEF feeder cells and Geltrex coated plates were confirmed by live staining with Tra-1-81 and Tra-1-60 antibodies (Invitrogen). Cells were washed with Knockout DMEM and stained with Tra-1-81 or Tra-1-60 antibodies at 1:200 dilutions for 1 h in the CO~2~ incubator. Cells were subsequently washed twice with Knockout DMEM and incubated with secondary anti-mouse antibody conjugated with Alexa Fluor 488 for one hour. Finally, cells were washed with Knockout DMEM and replenished with iPSC growth medium for microscopic imaging. Images were acquired using a Leica TCS SP5 Confocal Laser Scanning Microscope.

3.4.. iPSC karyotyping {#S7}
----------------------

Karyotyping of the iPSC was carried out at the CytoGenomics Core Laboratory (Brigham and Women\'s Hospital, Harvard Medical School, Boston, MA). G-banding was used to karyotype our iPSC line. Cells in a stage of active division in metaphase were arrested, harvested and fixed with methanol:acetic acid (3:1). The cell pellet was washed, re-suspended, dropped on a slide and dried on a hotplate. Cells were stained with Giemsa and the metaphase chromosome number from individual nuclei were imaged (Olympus BX51, 100×) and counted using the Cyto Vision Software.

3.5.. Three germ layer in vitro differentiation and characterization {#S8}
--------------------------------------------------------------------

The differentiation capability of iPSC lines was analyzed by the formation of EB, based on the previously published protocol ([@R2]; [@R6]). Briefly, undifferentiated iPSC colonies were transferred into the non-adherent poly-HEMA (Sigma) coated petri dish and were cultured in E6 medium without bFGF for 7 days. The resulting EB, which theoretically comprise three embryonic germ layers, were plated onto Geltrex coated tissue culture dishes and cultured for spontaneous differentiation. After cells were differentiated in EB culture for a total of 19 days, cells were fixed with 4% PFA and immuostained with three different antibodies (Ectoderm: β III tubulin, Sigma; Mesoderm: Smooth muscle actin, Invitrogen; Endoderm: Alpha fetoprotein, Invitrogen). Images were acquired using the Nikon TMS, 10×; the Leica TCS SP5 Confocal Microscope, 10×; and the AmScope microscope digital camera.

4.. Verification and authentication {#S9}
===================================

Karyotyping of our iPSC was performed and revealed by the microscope scan. All ten metaphase cells had 46 chromosomes and had XY sex chromosomes characteristic of a male patient ([Fig. 1](#F1){ref-type="fig"}).

We examined embryonic stem cell makers, Tra-1-81 and Tra-1-60 by live staining of cells and found all cells are Tra-1-81 ([Fig. 2A](#F2){ref-type="fig"}) and Tra-1-60 (not shown) positive, thus confirming iPSC purity and pluripotency.

The project described was supported by Award Number I21BX002215 (WX) from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development. The views expressed in this article are those of the authors and do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

![Karyotyping of Induced pluripotent stem cell I2-12F. Cells were stained with Giemsa and the metaphase chromosome number from individual nuclei were imaged and counted. All ten metaphase cells had 46 chromosomes and XY sex chromosomes characteristic of a male patient.](nihms-1057986-f0001){#F1}

![Characterization of iPSC I2-12F. Stem cell surface protein Sialylated Keratan Sulfate Antigen Tra-1-81 was present in all iPSC I2-12F (A, left; bright field: right). There is no trace of Sendai virus protein, detected by antibody against SeV protein (B, left), compared to positive cells of early stage (at passage five) when SeV protein was present.](nihms-1057986-f0002){#F2}

![Characterization of embryoid body (EB) formation. EBs was fixed with 4% PFA and immunostained with three different antibodies (ectoderm: β III tubulin, green; mesoderm: smooth muscle actin (SMA), red; endoderm: α-fetoprotein (AFP) green). Con: cells were stained in the absence of primary antibodies.](nihms-1057986-f0003){#F3}
